Joanne McLaurin Talks AZD-103 @ NeuroSci/07
Joanne McLaurin Inventor of AZD-103 speaks yesterday.
Read this then compare to the Human Results recently announced!!
Society for Neuroscience 2007 - Today, Session Title: Alzheimer's Disease: Anti-Abeta Therapies : Chair: DALE SCHENK (N.B. ELAN/TRANSITIONS' ELND-005/AZD-103)
Title: Properties of Scyllo-Inositol (AZD-103) as a therapeutic treatment of AD-like pathology
Location: San Diego Convention Center: Room 31C
Presentation Start/End Time: Tuesday, Nov 06, 2007, 4:00 PM - 4:15 PM
Authors: *J. MCLAURIN, D. FENILI, M. E. BROWN, R. V. RAPPAPORT;
Ctr. for Resch Neurodegen Dis., Univ. of Toronto, Toronto, ON, Canada
Abstract: Inositol is a simple polyol with eight naturally occurring stereoisomers. myo-Inositol, D-chiro- and epi-inositol have been examined as potential therapeutic agents for various diseases, with favourable results, but treatment with scyllo-inositol had not been previously investigated. Our laboratory has shown that scyllo-inositol inhibits cognitive deficits in TgCRND8 mice and significantly ameliorates disease pathology, suggesting it might be effective in treating Alzheimer’s disease. Here we show that scyllo-inositol has a sustained ability to treat animals at advanced stages of Alzheimer's disease-like pathology. Significant decreases in insoluble Aβ40 and Aβ42 and plaque accumulation were observed in the brains of treated versus untreated TgCRND8 mice. The growth of plaques of all sizes was inhibited by scyllo-inositol administration. We further show a dose-dependent decreases in amyloid pathology and cognitive deficits in the TgCRND8 mice. To demonstrate that scyllo-inositol effects were within the CNS, gas chromatography/mass spectrometry was used to examine myo- and scyllo-inositol concentrations after oral administration. Further we examined how closely scyllo- and myo-inositol are inter-regulated in the CNS and whether Scyllo-Inositol, if elevated within the CNS, would incorporate into phosphatidylinositol lipids. Cerebral spinal fluid levels of scyllo-inositol increased following Scyllo-Inositol treatment but not myo-inositol treatment. Scyllo-Inositol treatment also caused increased levels of scyllo-inositol in the brain. We further show that scyllo-inositol, even at elevated levels, does not incorporate into the phosphatidylinositol family of lipids. These combined results demonstrate that scyllo-inositol accumulates within the CNS up to 10 fold endogenous levels and does not interfere with phosphatidylinositol lipid production.
Disclosures: J. McLaurin , Transition Therapeutics, C. Other Research Support (receipt of drugs, supplies, equipment or other in-kind support); Patent, E. Ownership Interest (stock, stock options, patent or other intellectual property); D. Fenili, None; M.E. Brown, None; R.V. Rappaport, None.
Support:
---Canadian Institutes of Health Research
---Natural Science and Engineering Research Council
---Transition Therapeutics Inc.
Hmmmmm.......compellingly similar parrallels so far!!
Now if we get the same Parrallel in Phasell or lll as in above abstract...."We further show a dose-dependent decreases in amyloid pathology and cognitive deficits in the TgCRND8 mice."
Air tight case has been made so far..........